Alaunos Therapeutics Announces 2024 Annual Meeting and Proxy Statement

TL;DR

<b>Alaunos Therapeutics is holding its 2024 annual meeting on June 6, 2024, with a key proposal for a reverse stock split.</b>

AI Summary

Alaunos Therapeutics, Inc. (TCRT) filed a Proxy Statement (DEF 14A) with the SEC on April 26, 2024. The 2024 annual meeting of stockholders for Alaunos Therapeutics, Inc. will be held virtually on June 6, 2024. The meeting agenda includes electing five director nominees, ratifying RSM US LLP as the independent auditor, and approving executive compensation. A key proposal is to amend the company's charter to allow for a 1-for-5 to 1-for-20 reverse stock split. The company is seeking approval for amendments to its certificate of incorporation. The proxy statement was filed on April 26, 2024.

Why It Matters

For investors and stakeholders tracking Alaunos Therapeutics, Inc., this filing contains several important signals. The company is proposing a reverse stock split, which could significantly alter its share structure and potentially impact its stock price and market perception. The annual meeting will address critical corporate governance matters, including director elections and auditor ratification, alongside executive compensation approval.

Risk Assessment

Risk Level: low — Alaunos Therapeutics, Inc. shows low risk based on this filing. The filing is a routine proxy statement for an annual meeting and does not contain new financial performance data or significant operational updates, indicating a low level of immediate risk.

Analyst Insight

Stockholders should review the proposals, particularly the reverse stock split, and vote accordingly before the June 6, 2024 meeting.

Key Numbers

• 5 — Director Nominees (Proposal 1: To elect each of the five nominees for director)
• June 6, 2024 — Annual Meeting Date (To be Held on June 6, 2024)
• 2024 — Fiscal Year End (for its fiscal year ending December 31, 2024)
• 1-for-5 to 1-for-20 — Reverse Stock Split Ratio (effect a reverse stock split with respect to the Company's issued and outstanding common stock, at a reverse stock split ratio of 1-for-5 to 1-for-20)

Key Players & Entities

• Alaunos Therapeutics, Inc. (company) — Registrant
• June 6, 2024 (date) — Annual Meeting date
• RSM US LLP (company) — Independent registered public accounting firm
• April 26, 2024 (date) — Filing date
• 2025 (date) — Director term end year
• 1-for-5 to 1-for-20 (dollar_amount) — Reverse stock split ratio

FAQ

Risk Factors

• Reverse Stock Split Proposal [medium — financial]: The company proposes to amend its charter to effect a reverse stock split at a ratio of 1-for-5 to 1-for-20, subject to board discretion.

Industry Context

Alaunos Therapeutics, Inc. operates in the pharmaceutical preparations industry, focusing on developing therapies.

Regulatory Implications

The filing is a standard proxy statement (DEF 14A) under the Securities Exchange Act of 1934, requiring specific disclosures for shareholder meetings.

What Investors Should Do

1. Review the proxy statement for details on director nominees and their qualifications.
2. Evaluate the rationale and potential impact of the proposed reverse stock split.
3. Vote on all proposals before the June 6, 2024 Annual Meeting.

Key Dates

• 2024-06-06: Annual Meeting of Stockholders — Election of directors, auditor ratification, executive compensation approval, and reverse stock split proposal.
• 2024-04-26: Filing Date of Proxy Statement — Definitive Proxy Statement filed with the SEC.

Glossary

DEF 14A

Definitive Proxy Statement filed with the SEC. (Standard filing for annual meetings and other shareholder votes.)

Reverse Stock Split

A corporate action to reduce the number of outstanding shares of common stock. (A key proposal for shareholder approval at the meeting, potentially impacting share price and trading.)

Year-Over-Year Comparison

This filing is a proxy statement for the 2024 annual meeting, indicating routine corporate governance activities rather than a change in financial reporting from a previous period.

Key Financial Figures

• $0.001 — and outstanding common stock, par value $0.001 per share, including stock held by the

Filing Documents

• d778708ddef14a.htm (DEF 14A) — 506KB
• g778708g01g01.jpg (GRAPHIC) — 238KB
• g778708g02g02.jpg (GRAPHIC) — 160KB
• 0001193125-24-118247.txt (&nbsp;) — 1049KB

EXECUTIVE COMPENSATION

EXECUTIVE COMPENSATION 33 Summary Compensation Table 33 Narrative to the Summary Compensation Table 34 Pay Versus Performance 39 Role of our Compensation Committee, Management and Consultant 37 Outstanding Equity Awards at 2022 Fiscal Year-End 38 Stockholder Engagement 39 INFORMATION REGARDING THE BOARD AND CORPORATE GOVERNANCE 42 Independence of the Board 42 Board Leadership Structure 42 Nasdaq Board Diversity Matrix 42 Director Attendance at Board and Stockholder Meetings 43 Board Committees 43 Director Nomination Process 44 Risk Management and Oversight 45 Stockholder Communications with Directors 45 Code of Ethics and Business Conduct 46 Corporate Governance Guidelines 46 Whistleblower Policy 46 Corporate Governance Documents 46 Report of the Audit Committee 46 DIRECTOR COMPENSATION 48 Non-Employee Director Compensation 48 Director Compensation Table 48 SECURITIES AUTHORIZED FOR ISSUANCE UNDER EQUITY COMPENSATION PLANS 50 LIMITATION OF LIABILITY AND INDEMNIFICATION 51 CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS 52 Related-Party Transaction Policy 52 Certain Related-Party Transactions 52 DELINQUENT SECTION 16(A) REPORTS 55

SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND

SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT 56 HOUSEHOLDING OF PROXY MATERIALS 58 OTHER MATTERS 59 Annex A Third Amended and Restated Certificate of Incorporation A-1 Annex B Certificate of Amendment to Second Amended and Restated Certificate of Incorporation B-1 i Table of Contents Alaunos Therapeutics, Inc. 2617 Bissonnet, Suite 225, Houston, TX 77050 PROXY FOR THE ANNUAL MEETING OF STOCKHOLDERS To Be Held On June 6, 2024 QUESTIONS AND ANSWERS ABOUT THESE PROXY MATERIALS AND VOTING Who is soliciting my vote? We are providing you with these proxy materials because the board of directors (the Board) of Alaunos Therapeutics, Inc. (we, Alaunos or the Company) is soliciting your proxy to vote at the 2024 annual meeting (the Annual Meeting), including at any adjournments or postponements thereof. The Annual Meeting will be held on June 6, 2024 at 9:00 a.m., Eastern Time virtually and exclusively online via live audio-only webcast at www.virtualshareholdermeeting.com/TCRT2024. Why did I receive a notice regarding the availability of proxy materials through the internet? Pursuant to rules adopted by the Securities and Exchange Commission (the SEC), we have elected to provide access to our proxy materials over the internet. Accordingly, we have sent you a Notice of Internet Availability of Proxy Materials (the Notice) because the Board is soliciting your proxy to vote at the Annual Meeting, including at any adjournments or postponements thereof. All stockholders will have the ability to access the proxy materials through the website referred to in the Notice or to request a printed set of the proxy materials. Instructions on how to access the proxy materials over the internet or to request a printed set of the proxy materials may be found in the Notice. We intend to mail the Notice on or about April 26, 2024 to all stockholders of record entitled to vote at the Annual Meeting. Will I receive any ot

View Full Filing

View this DEF 14A filing on SEC EDGAR